In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

Question

Retroviral vector is introduced into these lymphocytes.

Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages

Lymphocytes from patient's blood are grown in culture, outside the body

Genetically engineered lymphocytes are not immortal cells.

Please login to view the detailed solution steps...